Last reviewed · How we verify

BROMHEXINE HYDROCHLORIDE

FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

BROMHEXINE HYDROCHLORIDE is a drug. It is currently FDA-approved.

Bromhexine hydrochloride is an intervention studied in clinical trials for various conditions, including Amyotrophic Lateral Sclerosis (ALS), COVID-19, Type I Gaucher Disease, and healthy individuals. It is being tested alongside other interventions, such as Ambroxol and Vitamin C, in a double-blind, randomized, placebo-controlled clinical trial for ALS treatment.

At a glance

Generic nameBROMHEXINE HYDROCHLORIDE
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BROMHEXINE HYDROCHLORIDE

What is BROMHEXINE HYDROCHLORIDE?

BROMHEXINE HYDROCHLORIDE is a Small molecule drug.

What development phase is BROMHEXINE HYDROCHLORIDE in?

BROMHEXINE HYDROCHLORIDE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing